Clinical Trial: NCT06498479
ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hansoh BioMedical R&D Company |
| Information Provided By: | Hansoh BioMedical R&D Company |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Official Title
ARTEMIS-008:A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Conditions
Small Cell Lung Cancer
Intervention / Treatment
- Drug: HS-20093
- Drug: Topotecan
Other Study ID Numbers
- HS-20093-301
Start Date (Actual)
2024-07-04
Primary Completion Date (Actual)
2026-08-20
Study Completion Date (Actual)
2026-08-20
Enrollment (Actual)
461
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hansoh BioMedical R&D Company |
| Information Provided By: | Hansoh BioMedical R&D Company |
| Last Update Posted: | 2026-10-16 |
Study Overview
Brief Summary
The main objective of this study is to compare the efficacy of HS-20093 with standard of care (SOC) on prolonging overall survival (OS) in subjects with relapsed small cell lung cancer (SCLC).
Official Title
ARTEMIS-008:A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Conditions
Small Cell Lung Cancer
Intervention / Treatment
- Drug: HS-20093
- Drug: Topotecan
Other Study ID Numbers
- HS-20093-301
Start Date (Actual)
2024-07-04
Primary Completion Date (Actual)
2026-08-20
Study Completion Date (Actual)
2026-08-20
Enrollment (Actual)
461
Study Type
Interventional
Phase
Phase 3